2-[[[2-[(Hydroxyacetyl)Amino]-4-Pyridinyl]Methyl]Thio]-N-[4-(Trifluoromethoxy)Phenyl]-3-Pyridinecarboxamide Benzenesulfonate, Crystal Of Same, Crystal Polymorph Thereof, And Methods For Production Thereof
Santen Pharmaceutical | Date: 2015-04-14
In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide(compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly. For solving these problems, we made examination focusing on the kind of the salt and, as a result, found that 1) benzenesulfonate of compound A does not decompose by light, humidity and other factors in a 1-week preliminary stability test (severe test), and has no problem in its storage stability, 2) a method of selectively producing two kinds of crystal forms of benzenesulfonate of compound A, and that 3) no mineral deposition in the stomach is observed even after a 4-week repeated oral administration.
Asahi Glass Co. and Santen Pharmaceutical | Date: 2014-11-17
To provide a composition for hair growth (hair growth agent) which has high hair growing effects and can be used for prevention or treatment of alopecia. The composition for hair growth comprises as an active ingredient at least one member selected from the group consisting of a compound represented by the formula (1) and a salt thereof. In the formula, R is a carboxy group or an alkoxycarbonyl group.
Santen Pharmaceutical | Date: 2014-05-27
A sealing label for wrapping a container including a container body and a lid portion, the sealing label includes an upper region covering the lid portion, a lower region covering the container body, a cutaway region disposed between the upper region and the lower region, and a tear-off line provided in a boundary between the cutaway region and the lower region as well as in a boundary between the cutaway region and the upper region. An identifying mark comprised of a shape, a pattern, a color or any combination thereof is provided to the lower region and a further identifying mark same as or similar to the identifying mark is provided to the upper region, a region comprised of the upper region and the cutaway region or a region comprised of the upper region, the cutaway region and the lower region.
Santen Pharmaceutical | Date: 2014-06-13
A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.
Santen Pharmaceutical | Date: 2014-03-12
A compound represented by the formula (1): wherein R1 represents a hydroxyl group, a dimethylphosphynoyloxy group, etc.; and R2 and R3 represent a methoxy group, etc.,or a pharmaceutically acceptable salt thereof can reduce a score of telangiectasia around the meibomian gland orifices and a number of obstruction at the orifices, so that it is useful as a prophylactic and/or therapeutic agent for meibomian gland dysfunction.